Current thinking and treatment practices in anaemia - An interactive poll

J. L. Spivak, M. Cazzola

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

At the recent EHA meeting in Birmingham, UK, an expert audience of haematologists and oncologists were polled using keypad technology on current thinking and treatment practices in anaemia in cancer patients. More than 76% of the audience thought that anaemia had a significant negative impact on the quality of life of cancer patients. The majority (> 60%) would institute treatment on the basis of appropriate symptoms rather than haemoglobin level, although among those who would use haemoglobin levels, there was no consensus on the concentration at which they would start treatment. The majority of respondents (54%) chose not to use the serum erythropoietin level as a guide as to when to institute therapy with recombinant human erythropoietin (rHuEPO) but, of those who would use it, 55% would use only the haemoglobin or haematocrit to identify those responding within the first 2-4 weeks of treatment. The remainder of the session used three case studies to investigate current treatment practices.

Original languageEnglish
JournalMedical Oncology
Volume17
Issue numberSUPPL. 1
Publication statusPublished - 2000

Fingerprint

Anemia
Hemoglobins
Erythropoietin
Therapeutics
Hematocrit
Neoplasms
Quality of Life
Technology
Serum

Keywords

  • Anaemia
  • Cancer
  • Case studies
  • Recombinant human erythropoietin
  • Treatment practices

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Current thinking and treatment practices in anaemia - An interactive poll. / Spivak, J. L.; Cazzola, M.

In: Medical Oncology, Vol. 17, No. SUPPL. 1, 2000.

Research output: Contribution to journalArticle

@article{7057db7728764e96bf1bc0e07066aaa8,
title = "Current thinking and treatment practices in anaemia - An interactive poll",
abstract = "At the recent EHA meeting in Birmingham, UK, an expert audience of haematologists and oncologists were polled using keypad technology on current thinking and treatment practices in anaemia in cancer patients. More than 76{\%} of the audience thought that anaemia had a significant negative impact on the quality of life of cancer patients. The majority (> 60{\%}) would institute treatment on the basis of appropriate symptoms rather than haemoglobin level, although among those who would use haemoglobin levels, there was no consensus on the concentration at which they would start treatment. The majority of respondents (54{\%}) chose not to use the serum erythropoietin level as a guide as to when to institute therapy with recombinant human erythropoietin (rHuEPO) but, of those who would use it, 55{\%} would use only the haemoglobin or haematocrit to identify those responding within the first 2-4 weeks of treatment. The remainder of the session used three case studies to investigate current treatment practices.",
keywords = "Anaemia, Cancer, Case studies, Recombinant human erythropoietin, Treatment practices",
author = "Spivak, {J. L.} and M. Cazzola",
year = "2000",
language = "English",
volume = "17",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Current thinking and treatment practices in anaemia - An interactive poll

AU - Spivak, J. L.

AU - Cazzola, M.

PY - 2000

Y1 - 2000

N2 - At the recent EHA meeting in Birmingham, UK, an expert audience of haematologists and oncologists were polled using keypad technology on current thinking and treatment practices in anaemia in cancer patients. More than 76% of the audience thought that anaemia had a significant negative impact on the quality of life of cancer patients. The majority (> 60%) would institute treatment on the basis of appropriate symptoms rather than haemoglobin level, although among those who would use haemoglobin levels, there was no consensus on the concentration at which they would start treatment. The majority of respondents (54%) chose not to use the serum erythropoietin level as a guide as to when to institute therapy with recombinant human erythropoietin (rHuEPO) but, of those who would use it, 55% would use only the haemoglobin or haematocrit to identify those responding within the first 2-4 weeks of treatment. The remainder of the session used three case studies to investigate current treatment practices.

AB - At the recent EHA meeting in Birmingham, UK, an expert audience of haematologists and oncologists were polled using keypad technology on current thinking and treatment practices in anaemia in cancer patients. More than 76% of the audience thought that anaemia had a significant negative impact on the quality of life of cancer patients. The majority (> 60%) would institute treatment on the basis of appropriate symptoms rather than haemoglobin level, although among those who would use haemoglobin levels, there was no consensus on the concentration at which they would start treatment. The majority of respondents (54%) chose not to use the serum erythropoietin level as a guide as to when to institute therapy with recombinant human erythropoietin (rHuEPO) but, of those who would use it, 55% would use only the haemoglobin or haematocrit to identify those responding within the first 2-4 weeks of treatment. The remainder of the session used three case studies to investigate current treatment practices.

KW - Anaemia

KW - Cancer

KW - Case studies

KW - Recombinant human erythropoietin

KW - Treatment practices

UR - http://www.scopus.com/inward/record.url?scp=0034533658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034533658&partnerID=8YFLogxK

M3 - Article

C2 - 11188784

AN - SCOPUS:0034533658

VL - 17

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - SUPPL. 1

ER -